Nanotechnology approach for inhalation therapies
This invention relates to lipid nanoparticle compositions and methods for the localized delivery of active agents via inhalation therapy.
1. A composition comprising a plurality of lipid nanoparticles, wherein at least one lipid nanoparticle comprises:
(i) a lipid membrane surrounding an inner compartment of the nanoparticle,
(ii) an aqueous phase encapsulated by the inner compartment,
(iii) an active ingredient contained within the lipid membrane of the nanoparticle, wherein the active ingredient is prostaglandins, and
(iv) siRNA bound to the lipid nanoparticle via a cationic agent or bound to an outer lipid surface of the lipid nanoparticle via a disulfide bond,
wherein each lipid nanoparticle has a diameter ranging from 1 nm to 1000 nm.
2. A composition comprising a plurality of lipid nanoparticles, wherein at least one lipid nanoparticle comprises:
(i) a mixture of solid and liquid lipids and
(ii) at least one lipid-soluble active agent contained within the lipid mixture, wherein the active agent is prostaglandins, and
(iii) siRNA bound to the lipid nanoparticle via a cationic agent or bound to an outer lipid surface of the lipid nanoparticle via a disulfide bond,
wherein each lipid nanoparticle has a diameter ranging from 1 nm to 1000 nm.
3. The composition of claim 1 , wherein the active agent is prostaglandin E2.
4. The composition of claim 1 , further comprising, in combination with the plurality of lipid nanoparticles, one or more pharmaceutical excipients selected from the group consisting of humectants, viscosity modifiers, surfactants, pH stabilizers, freeze drying protectants, polymers, and combinations thereof.
5. The composition of claim 2 , further comprising, in combination with the plurality of lipid nanoparticles, one or more pharmaceutical excipients selected from the group consisting of humectants, viscosity modifiers, surfactants, pH stabilizers, freeze drying protectants, polymers, and combinations thereof.
6. The composition of claim 1 , further comprising one or more additional ingredients contained within the lipid nanoparticle or bound to an outer lipid surface of the lipid nanoparticle, wherein the one or more additional ingredients are selected from the group consisting of anti-histaminic agents, anti-inflammatory agents, corticosteroids, nucleic acids, peptides, proteins, oligonucleotides, enzyme imaging agents, fluorescent dyes and combinations thereof.
7. The composition of claim 2 , further comprising one or more additional ingredients contained within the lipid nanoparticle or bound to an outer lipid surface of the lipid nanoparticle, wherein the one or more additional ingredients are selected from the group consisting of anti-histaminic agents, anti-inflammatory agents, corticosteroids, nucleic acids, peptides, proteins, oligonucleotides, enzyme imaging agents, fluorescent dyes and combinations thereof.
8. The composition of claim 6 , wherein the additional ingredient is a cyclooxygenase inhibitor.
9. The composition of claim 7 , wherein the additional ingredient is a cyclooxygenase inhibitor.
10. The composition of claim 1 , wherein the lipid nanoparticle further comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol) bound to an outer lipid surface of the lipid nanoparticle.
11. The composition of claim 2 , wherein the lipid nanoparticle further comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol) bound to an outer lipid surface of the lipid nanoparticle.
12. The composition of claim 1 , wherein the lipid nanoparticle further comprises cholesterol incorporated into the lipid membrane.